Ramon Alemany, Ph.D.

Ramon Alemany, Ph.D., is a pioneer and expert on oncolytic adenoviruses. Dr. Alemany is Head of the Immunotherapy and Virotherapy Group at the ProCURE Program of the Catalan Institute of Oncology (ICO) and the Oncobell Program of the Biomedical Research Institute of Bellvitge (IDIBELL) in Spain. He is co-founder of VCN Biosciences (now Theriva Biologics S.L.), a consultant for several virotherapy companies, and former President of the Spanish Society of Gene and Cell Therapy. Following Dr. Alemany’s Ph.D., at the University of Barcelona, he focused on the development of adenovirus vectors expressing anti-K-Ras and p53 at the MD Anderson Cancer Center (Houston, TX). Dr. Alemany has held leading research positions at the Gene Therapy Unit at Baxter Healthcare (Round Lake, IL) and at the University of Alabama (Birmingham, AL), where he collaborated with a team of top-level virologists. Dr. Alemany is the inventor of 15 oncolytic adenoviruses patents to date and has an outstanding publication record, with more than 160 papers. He also serves as editor in several gene therapy journals.